Alzheimer’s Disease | Current Treatment | US | 2016

With no significant drug launches occurring in more than a decade, the overarching treatment paradigms in Alzheimer’s disease (AD) are mostly stable. However, understanding what factors and forces drive neurologists’ clinical decision making across the AD spectrum today provides crucial context for a future market landscape set to expand meaningfully—thanks to a highly dynamic pipeline composed of potentially landmark disease-modifying therapies, new procognitive symptomatic adjuncts, and targeted behavioral treatments. The Current Treatment Overview provides insight into how AD is diagnosed and treated today, while the detailed, expanded analysis for the United States offers deep insights regarding the AD treatment algorithm, supported by real-world evidence where possible, and the rationale behind neurologists’ treatment decisions.

Login to access report

launch Related Market Assessment Reports